Identification of Allosteric Inhibitors of p21-Activated Kinase

  • Julien Viaud
  • Jeffrey R. PetersonEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 928)


Protein kinases are among the most important drug targets; however the structural conservation of the ATP-binding pocket of kinases can lead to promiscuous inhibition of additional unintended kinase targets. Allosteric inhibitors that target less conserved regions of protein kinases represent an alternative approach that may provide more selective kinase inhibition. In this report, protocols are provided for the screening and identification of Pak1 inhibitors acting via an allosteric mechanism.

Key words

Kinase inhibitor Protein kinase Pak kinase Autoinhibition Allosteric inhibition Cdc42 Rho GTPases GTP-binding protein 



This work described here was supported by a W.W. Smith Foundation Award and an American Cancer Society Scholar Award to J.R.P. and by a National Institutes of Health (NIH) award RO1 GM083025 to J.R.P.

J.V. was supported by a grant from the Fondation pour la Recherche Médicale.


  1. 1.
    Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199–204PubMedCrossRefGoogle Scholar
  2. 2.
    Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15:322–331PubMedCrossRefGoogle Scholar
  3. 3.
    Viaud J, Peterson JR (2009) An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 8:2559–2565PubMedCrossRefGoogle Scholar
  4. 4.
    Eswaran J, Soundararajan M, Knapp S (2009) Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 28:209–217PubMedCrossRefGoogle Scholar
  5. 5.
    Vadlamudi RK, Kumar R (2003) P21-activated kinases in human cancer. Cancer Metastasis Rev 22:385–393PubMedCrossRefGoogle Scholar
  6. 6.
    Vadlamudi RK, Kumar R (2004) p21-activated kinase 1: an emerging therapeutic target. Cancer Treat Res 119:77–88PubMedCrossRefGoogle Scholar
  7. 7.
    Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6:459–471PubMedCrossRefGoogle Scholar
  8. 8.
    Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC (2000) Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102: 387–397PubMedCrossRefGoogle Scholar
  9. 9.
    Parrini MC, Lei M, Harrison SC, Mayer BJ (2002) Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell 9:73–83PubMedCrossRefGoogle Scholar
  10. 10.
    Strochlic TI, Viaud J, Rennefahrt UE, Anastassiadis T, Peterson JR (2010) Phosphoinositides are essential coactivators for p21-activated kinase 1. Mol Cell 40: 493–500PubMedCrossRefGoogle Scholar
  11. 11.
    Gatti A, Huang Z, Tuazon PT, Traugh JA (1999) Multisite autophosphorylation of p21-activated protein kinase gamma-PAK as a function of activation. J Biol Chem 274: 8022–8028PubMedCrossRefGoogle Scholar
  12. 12.
    Koresawa M, Okabe T (2004) High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev Technol 2:153–160PubMedCrossRefGoogle Scholar
  13. 13.
    Prowse CN, Hagopian JC, Cobb MH, Ahn NG, Lew J (2000) Catalytic reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry 39:6258–6266PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Cancer Biology ProgramFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations